Featured

In the biopharma industry, selecting the right contract development and manufacturing organization (CDMO) is pivotal to a successful pharmaceutical development journey. This decision hinges on two critical factors: a customer-centric approach and team cohesion. In this blog, we explore...

The API CDMO market underwent significant changes due to the COVID-19 pandemic. The global rollout of vaccines and therapeutics against the virus led to an unprecedented surge in demand for CDMO (Contract Development and Manufacturing Organization) services. CDMOs played...

Contract Development and Manufacturing Organizations (CDMOs) specializing in packaging offer an extensive array of services that encompass multiple facets of the pharmaceutical industry. These services span from product development and clinical as well as commercial Active Pharmaceutical Ingredient (API)...

The global market for cell and gene therapy biomanufacturing Contract Development and Manufacturing Organizations (CDMOs), with a specific focus on Adeno-Associated Virus (AAV), witnessed remarkable growth, valued at $0.2313 billion in 2022. Projections indicate that by 2033, this market...

Pharmaceutical products undergo an extensive journey from lab to patient, traversing various modes of transportation in the supply chain. The last leg of this journey, known as the "last mile," becomes particularly complex in the cold chain. This stage...

Contract Development and Manufacturing Organizations (CDMOs), which pharmaceutical companies increasingly delegate product development and manufacturing, operate in a fragmented market undergoing substantial consolidation. Yet, many CDMOs fail to fully capitalize on pricing projects, risking competitiveness. To thrive, they must...

According to insights, the pharmaceutical CDMO market is projected to grow at a Compound Annual Growth Rate (CAGR) of 7.29% until 2028. This growth could be attributed to the expanding pharmaceutical sector, driven by the increasing usage of analytics...